Gene Bridges licenses Red/ET Recombineering to Genencor

Business Wire, March 31, 2008

HEIDELBERG, Germany -- Gene Bridges GmbH, the recombineering company, today announced that Genencor International Inc. USA, a part of Danisco US Inc., has completed a commercial license agreement for the use of the Red/ET recombination technology from Gene Bridges.

Under the terms of the agreement, Gene Bridges has licensed the Red/ET technology to Genencor for the purpose of genetically engineering recombinant micro-organisms for use in industrial applications. No financial details were disclosed.

Gary Stevens, CEO of Gene Bridges GmbH, commented:

'We are very pleased to add Danisco to the list of major industrial biotechnology companies using Red/ET. Recombineering is the technology of choice in DNA engineering and is used worldwide in industry and academia.'

Red/ET is a revolutionary method for DNA engineering. Recombineering with Red/ET allows unlimited cloning, subcloning, and modification of DNA at any chosen position. It permits precise engineering of DNA molecules of any size, including very large ones such as BACs or the E.coli chromosome. Recombineering DNA using Red/ET has a number of advantages over conventional methods:

* Independent of restriction sites

* No size limits

* No unwanted mutations

* Rapid

Red/ET Recombineering is one simple and powerful tool to modify plasmids, BACs, and even E.coli chromosomes.

About Gene Bridges GmbH

Gene Bridges GmbH is a self-financed biotech company pioneering recombineering, the fast and precise method of engineering gene sequences. The Company was founded in 2000 as spin-off from the European Molecular Biology Laboratory (EMBL) in Heidelberg, Germany. Gene Bridges commercialises its patented recombineering technology from its facilities in Heidelberg as well as through its distributors worldwide. Further information can be found by visiting www.genebridges.com.